Stefan Oelrich

Stability in Motion

Amid global uncertainty, Bayer Pharma, led by Stefan Oelrich, pursues strategic transformation to boost resilience, drive innovation, and secure sustainable growth in a changing healthcare landscape.

Top-Feature

Concept Heidelberg

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Interview

Strategic Response to a Shifting Pharma Landscape

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Bayer AG

Stefan Oelrich

Stability in Motion

Top-Feature

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Brenntag Downsizes Management Board, Retains Both Divisions

Advanced Recycling Conference 2025: New Paths to the Circular Economy

A successful concept on course for expansion — maintenance Munich 2025

20 Years of CHEManager International

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Interview

Stability in Motion

Newsletter & e-edition